


FINAL PROGRAM 2020



EuroValve

October 20 - 21, 2020



VIRTUAL CONGRESS

COURSE DIRECTORS

Patrizio Lancellotti, *Liege, Belgium*

Khalil Fattouch, *Palermo, Italy*

Gilbert Habib, *Marseille, France*


José-Luis Zamorano, *Madrid, Spain*

Phillippe Pibarot, *Québec, Canada*

Mani Vannan, *Atlanta, USA*

Jeroen J. Bax, *Leiden, The Netherlands*

www.eurovalvecongress.com



EDITO

Dear colleagues and friends,

We are happy to welcome you at the first Eurovalve Virtual congress from Tuesday October 20 to Wednesday October 21.

Are you registered? You have received the terms and conditions of connection.

You are not yet registered? Contact Heloise Marty hmarty@divine-id.com.

See you online!

Kind regards

The courses directors : Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib, José-Luis Zamorano, Philippe Pibarot, Mani Vannan, Jeroen J. Bax



Eurovalve congress 2020 is compliant with Ethical Medtech business code of practise.



Visa N° 20/V2/13034/007274

Event endorsed by



PROGRAM CHAIRS

Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib, José-Luis Zamorano, Philippe Pibarot, Mani Vannan, Jeroen J. Bax.

FACULTY

Jeroen Bax, Leiden, The Netherlands

Bernard Cosyns, Brussels, Belgium

Khalil Fattouch, Palermo, Italy

Madalina Garbi, Cambridge, UK

Gilbert Habib, Marseille, France

Patrizio Lancellotti, Liege, Belgium

Cécile Oury, Liege, Belgium

Philippe Pibarot, Montréal, Canada

Marc Radermecker, Liege, Belgium

Mani Vannan, Atlanta, USA

José Luis Zamorano, Madrid, Spain

SYNOPTIC

TUESDAY OCTOBER 20, 2020	
14:00	Update on valvular heart disease registries: the big picture
15:15	Flash News: Pending issues in transcatheter aortic valve treatment
16:00	Industry symposium - Cancelled

WEDNESDAY OCTOBER 21, 2020	
13:30	Industry symposium
14:30	Difficult issues in the management of valvular heart diseases
15:45	Industry symposium
16:15	Flash news
16:45	End of the sessions

TUESDAY OCTOBER 20 2020

- 14:00 Update on valvular heart disease registries: the big picture
(ESC Core Curriculum in VHD)
Chairmen: Patrizio Lancellotti, Marc Radermecker
- 14:00 Tricuspid regurgitation: Less and less forgotten. *José-Luis Zamorano*
- 14:20 Infective endocarditis: Changing epidemiology and outcome? *Gilbert Habib*
- 14:40 Bicuspid Aortic Valve: Demographics and natural history. *Jeroen Bax*
- 15:15 Flash news: pending issues in transcatheter aortic valve treatment
Chairmen: Chairmen: Patrizio Lancellotti, Marc Radermecker
TAVI for asymptomatic severe aortic stenosis – the next frontier. *Philippe Pibarot*
- 16:00 Industry symposium - **Cancelled**
(See p.5)

WEDNESDAY OCTOBER 21 2020

- 13:30 **Industry symposium**
(See p.5)
- 14:30 **Difficult issues in the management of valvular heart diseases**
(ESC Core Curriculum in VHD)
Chairmen: Jeroen Bax, Madalina Garbi, Patrizio Lancellotti
- 14:30 Aortic regurgitation remains off-limits for TAVI? **Philippe Pibarot**
- 14:50 Tailoring antithrombotic therapy to the TAVI patient. **Cécile Oury**
- 15:10 Infective endocarditis and Cancer: data from EuroEndo. **Bernard Cosyns**
- 15:45 **Industry symposium**
(See p.5)
- 16:15 **Flash News**
Chairmen: Jeroen Bax, Erwan Donal, Madalina Garbi, Patrizio Lancellotti
Are all patients with degenerative mitral regurgitation the same? **Mani Vannan**
- 16:45 **End of the sessions**

INDUSTRY SYMPOSIA

TUESDAY OCTOBER 20

16:00 **PHILIPS** - Cancelled
16:20

Chairmen : Jeroen Bax, Mani Vannan
Future directions in SHD imaging
Niels Nijhof, Senior Scientist, Philips

WEDNESDAY OCTOBER 21

13:30
14:30



Chairman : Jeroen Bax, Madalina Garbi, Patrizio Lancellotti
Benefits of new quantification & visualization tools to better understand the tricuspid pathologies & impact on treatment decisions

How fundamental is the imaging for the challenges of tricuspid valve repair!
– Epidemiology and prognosis according to current techniques availables
– Case report of a patient treated by tricuspid clip for a isolated tricuspid regurgitation
Erwan Donal

How to assess TR in 2020 ? **Augustin Coisne**

15:45 **SIEMENS**
16:15 **Healthineers** 

Chairmen : Gilbert Habib, Patrizio Lancellotti, Philippe Pibarot
Role of Intra-cardiac Echo in Tricuspid and Mitral Valve Clip for TR and MR.
Mani Vannan

PRACTICAL INFORMATION

LIVE SESSIONS

Tuesday October 20: 02.00pm – 04.20pm

Wednesday October 21: 01.30pm – 04 :45pm

HOW TO CONNECT

You must be registered for the virtual congress.
The login links are in the newsletter practical information.

You can log in from 13:30 on Tuesday October 20 and from 13:00 on Wednesday October 21.

A question? Please contact Stéphanie Meyer +336 46 10 48 26
smeyer@divine-id.com

PROGRAM

See the program

Visit our website eurovalvecongress.com



Event endorsed by ESC Council Valvular Heart Disease



EUROVALVE CONGRESS 2020 has been accredited by **CME** credits by the **EBAC** (except sponsored symposia). *Get your EBAC credit points no matter if you follow the meeting online. In order to get the online certificate, you must attend more than 100% of the live.*



Eurovalve congress 2020 is compliant with **Ethical Medtech** business code of practise



divine [id] received **MedTech Europe Ethical Charter** certification

**WE HAVE EVERY SINGLE MOMENT AT HEART.
JUST LIKE YOU DO.**



Everyone's life is full of single precious moments. We at Daiichi Sankyo know how much every one of them matters. This is why we are committed to bringing effective cardiovascular therapeutic options to our patients. To help them - and those who stand beside them - enjoy their lives to the fullest.
WE CARE FOR EVERY HEARTBEAT.



Lower MR Grades Are Within Your *Clasp*

PASCAL Repair System **More Opportunity, Lower MR Grades**

Do you aspire to reach MR 0-1+ more often?

A system intentionally designed to help you reach lower mitral regurgitation grades with lower gradients. Capture, release, and navigate with more confidence to pursue an MR 0-1+ result.



Find out more at [Edwards.com/PASCAL](https://www.edwards.com/PASCAL)

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult [eifu.edwards.com](https://www.edwards.com) where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, and PASCAL are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. E10689/02-20/TMTT

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](https://www.edwards.com)



Edwards

Eliquis[®]
apixaban

ELIQUIS[®] FILM-COATED TABLETS

20 x 2,5 mg	€ 49,39
60 x 2,5 mg	€ 86,63
168 x 2,5 mg	€ 225,91
56 x 5 mg	€ 81,47
168 x 5 mg	€ 225,91



The most prescribed NOAC worldwide, in Belgium and in Luxemburg^{1,2}



**OPTIMAL
PROTECTION**^{3*}



**EFFICACY
& SAFETY**³



SIMPLE[#]

- * Only ELIQUIS[®] offers at the same time (vs warfarine):
- Superiority demonstrated on stroke / systemic embolism (p=0.01)
 - Superiority demonstrated on major bleeding (p < 0.001)
 - Superiority demonstrated on all cause-mortality (p=0.047)

Only ELIQUIS[®] does not require dose adjustment for normal to moderate renal insufficiency⁴

There is a risk minimisation plan (RMP) for this product. Please consult/download the material on the FAMHP website:
https://www.afmps.be/fr/humain/medicaments/medicaments/bon_usage/programme_de_gestion_de_risques/rma • https://www.fagg.be/nl/MENSELIJK_gebruik/geneesmiddelen/geneesmiddelen/goed_gebruik_geneesmiddel/risicobeheerprogramma/rma

Please consult the SmPC for information related to the safety of this product.

1. IQVIA LMPB-LMPL, Days of Treatment volume a calculation of IQVIA Standard Units, Q4 2019, divided by recommended administration of each NOAC within 24hrs. [apixaban BID, dabigatran BID, edoxaban QD, rivaroxaban QD]. 2. IQVIA MIDAS, Days of Treatment volume a calculation of IQVIA Standard Units, Q2 2019, divided by recommended administration of each NOAC within 24hrs. [apixaban BID, dabigatran BID, edoxaban QD, rivaroxaban QD]. 3. Granger CB et al. N Engl J Med 2011; 365, 981-992. 4. ELIQUIS[®] (apixaban) Summary of Product Characteristics. Available at <http://www.ema.europa.eu>
Date of Preparation: February 2020. Job code: 432BE2000768-01.



Bristol-Myers Squibb



PERCEVAL® PLUS THE OPTIMAL MIX

Facilitates
Minimally Invasive Surgery



UNIQUELY SUITED
FOR VIV* PROCEDURES



VIABLE FOR
MULTIPLE VALVE
PROCEDURES



Available to a
Wide Patient Population

* Valve-in-Valve



SIMPLIFIES COMPLEX
PROCEDURES



Designed for Durability



BASED ON A
CLINICALLY
PROVEN
TECHNOLOGY



FREE

INNOVATIVE FREE TISSUE
TREATMENT

INDICATIONS: Europe - The Perceval Plus prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. **TOP POTENTIAL SIDE EFFECTS:** The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the Perceval Plus prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. The decision to make a transcatheter aortic valve implantation in Perceval Plus compared to other options should be done by the Heart team based on individual assessment of the patient's conditions. The safety and efficacy of Valve-in-Valve procedures in a Perceval Plus valve have not been established. Valve-in-Valve procedures in a Perceval Plus valve should be performed according to indications provided by the transcatheter valve manufacturer. The decision of using Perceval Plus in patients should be based on a careful individual assessment and limited to cases in which the benefits of using Perceval Plus justify the risks. The available clinical data indicate that using Perceval Plus in patients with other prostheses may result in intraoperative valve misplacement or insufficient leaflet coaptation leading to valve replacement, due to possible interference with the other prostheses. **MRI conditional.** For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Follow your labeling.

Manufactured by:

Sorin Group Italia Srl

A wholly-owned subsidiary of LivaNova PLC
Via Crescentino - 13040 Saluggia (VC) Italy
Tel: +39 0161 487472 - Fax: +39 0161 487316
info.cardiacsurgery@livanova.com

LivaNova Canada Corp.

5005 North Fraser Way
Burnaby BC V5J5M1 - Canada
Tel: 1-604-412-5650

www.livanova.com



CE 0123

© 2019 LivaNova all rights reserved.

Perceval Plus, an ideal solution for minimally invasive surgery, makes sutureless aortic valve replacement available to a wide patient population • Designed for valve durability • Based on more than 10 years of successful clinical experience with Perceval.



Registration and login

Please contact
smeyer@divine-id.com
+336 46 10 48 26

EuroValve

ACKNOWLEDGEMENTS 2020

SILVER SPONSORS



OTHER SPONSORS

